VEGFA and Hand-foot syndrome: mPFS = 14.4 weeks (HR+ = 23.1 and TNBC = 7.7 weeks), PR: 24% (TNBC 1/6 pts and HR+ 8/23 pts). G3/4 toxicity at expansion cohort included hand-foot syndrome (10%) and pleural effusion (10%), vomiting, rash, and mucositis (6.7% each), diarrhea, fatigue, dyspnoa, headache, and pain (3.3% each). Decreases in plasma VEGF-A and increases in VEGFR-2 were reported